Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Raw Materials (2016 - 2026)

Ocular Therapeutix has reported Raw Materials over the past 13 years, most recently at $287000.0 for Q1 2026.

  • For Q1 2026, Raw Materials rose 53.48% year-over-year to $287000.0; the TTM value through Mar 2026 reached $287000.0, up 53.48%, while the annual FY2025 figure was $202000.0, 5.61% down from the prior year.
  • Raw Materials for Q1 2026 was $287000.0 at Ocular Therapeutix, up from $202000.0 in the prior quarter.
  • Over five years, Raw Materials peaked at $341000.0 in Q2 2023 and troughed at $187000.0 in Q1 2025.
  • A 5-year average of $269235.3 and a median of $287000.0 in 2026 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: tumbled 43.16% in 2025 and later skyrocketed 53.48% in 2026.
  • Year by year, Raw Materials stood at $309000.0 in 2022, then decreased by 2.27% to $302000.0 in 2023, then fell by 29.14% to $214000.0 in 2024, then dropped by 5.61% to $202000.0 in 2025, then surged by 42.08% to $287000.0 in 2026.
  • Business Quant data shows Raw Materials for OCUL at $287000.0 in Q1 2026, $202000.0 in Q4 2025, and $229000.0 in Q3 2025.